iKinnect2.0 App for Suicide Risk in Youth
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an app called iKinnect2.0 to help reduce suicide risk in young people involved with the juvenile justice system. The study compares iKinnect2.0 with a control app, Life360, to determine which provides more effective support to youth and their caregivers. The trial targets youth aged 15-21 who have been arrested and are at significant risk for suicide, along with their primary caregivers. The goal is to assess whether the app can improve coping strategies and parent-youth relationships, ultimately reducing the risk of suicide. Participants will use the app regularly over a 16-week period. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could significantly impact the well-being of at-risk youth.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What prior data suggests that the iKinnect2.0 app is safe for youth?
Research shows that iKinnect2.0 aims to reduce risky behaviors in young people, including those related to suicide and self-harm. Although specific safety data on the iKinnect2.0 app is not available, the app serves as a tool to prevent harmful actions by providing support and resources to improve mental health.
The study is labeled as "Not Applicable" in terms of phase, indicating it is not a traditional drug or medical device trial. Instead, it examines the app's usage and its impact on behavior. Generally, mental health support apps are considered safe, as they do not involve invasive procedures or medications.
In summary, while specific safety data for iKinnect2.0 is lacking, the app aims to create a safe and supportive environment to help young people manage suicidal thoughts and behaviors. Prospective participants should know that the app's primary purpose is to offer mental health resources and support, which are generally safe.12345Why are researchers excited about this trial?
Researchers are excited about the iKinnect2.0 app because it offers a novel approach to managing suicide risk in youth through digital intervention. Unlike traditional therapies that often require in-person sessions with mental health professionals, iKinnect2.0 provides a convenient, accessible option that can be used anytime via a mobile app. This app is designed to engage users multiple times a day, potentially increasing its effectiveness by integrating support into daily life. By leveraging technology, iKinnect2.0 aims to provide timely resources and support, which could significantly enhance existing treatment methods for young people at risk.
What evidence suggests that the iKinnect2.0 app is effective for reducing suicide risk in youth?
Research has shown that iKinnect2.0, an app tested in this trial, might help reduce suicidal thoughts and behaviors in young people within the juvenile justice system. Studies have found that users of iKinnect2.0 report fewer issues with self-harm and behavior. Additionally, parents of these young people often feel more confident in preventing suicide and managing parenting challenges. The app includes tools to help young people manage stress and improve mental health. These early results suggest it could effectively prevent suicide.12356
Who Is on the Research Team?
Cindy Schaeffer, PhD
Principal Investigator
University of Maryland
Linda A. Dimeff, PhD
Principal Investigator
Evidence-Based Practice Institute
Are You a Good Fit for This Trial?
This trial is for English-speaking youth aged 15-21 at high risk of suicide, with a history of self-harm or attempts, who use a smartphone with data and live with their primary caregiver. Caregivers must also participate, be fluent in English, and have a smartphone. Youth should be involved in juvenile justice services.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pilot Testing
Usability and acceptability testing of iKinnect2.0 features with target end-users and stakeholders
Randomized Controlled Trial
Participants are randomly assigned to iKinnect2.0 or Life360 control app for a 16-week trial to test the efficacy of iKinnect2.0 in reducing suicidal behaviors and improving coping strategies
Follow-up
Participants are monitored for safety and effectiveness after the trial
What Are the Treatments Tested in This Trial?
Interventions
- Active Control App
- iKinnect2.0
Find a Clinic Near You
Who Is Running the Clinical Trial?
Evidence-Based Practice Institute, Seattle, WA
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator
University of Maryland
Collaborator